{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:12Z","timestamp":1790009052580,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ahj.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T18:34:15Z","timestamp":1507833255000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study"],"prefix":"10.1016","volume":"196","author":[{"given":"Uchenna","family":"Anyanwagu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil","family":"Mamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskandar","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ahj.2017.10.003_bb0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"9677","key":"10.1016\/j.ahj.2017.10.003_bb0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"issue":"9702","key":"10.1016\/j.ahj.2017.10.003_bb0015","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Diabetes Prevention Program Research Group","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ahj.2017.10.003_bb0020","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenia samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophr Bull"},{"issue":"1","key":"10.1016\/j.ahj.2017.10.003_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ahj.2017.10.003_bb0030","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes\u2014causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2017.10.003_bb0035","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"The Action to Control Cardiovascular risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"9933","key":"10.1016\/j.ahj.2017.10.003_bb0040","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","article-title":"Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes","volume":"383","author":"Holman","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ahj.2017.10.003_bb0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1463-1326.2008.00981.x","article-title":"Insulin therapy in type 2 diabetes: what is the evidence?","volume":"11","author":"Van Avendonk","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ahj.2017.10.003_bb0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"10.1016\/j.ahj.2017.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1001\/jama.2014.4312","article-title":"Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes","volume":"311","author":"Roumie","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahj.2017.10.003_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/dc10-1318","article-title":"A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study","volume":"34","author":"Colayco","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2017.10.003_bb0065","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2017.10.003_bb0070","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1111\/j.1755-5922.2010.00256.x","article-title":"The cardiovascular effects of GLP-1 receptor agonists","volume":"30","author":"Okerson","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ahj.2017.10.003_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2011\/215764","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials","volume":"2011","author":"Monami","year":"2011","journal-title":"Exp Diabetes Res"},{"issue":"4","key":"10.1016\/j.ahj.2017.10.003_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2017.10.003_bb0085","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacc.2015.12.058","article-title":"Incretin-based therapy for diabetes: what a cardiologist needs to know","volume":"67","author":"Waldrop","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2017.10.003_bb0090","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"issue":"4","key":"10.1016\/j.ahj.2017.10.003_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ahj.2017.10.003_bb0100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archinternmed.2012.1938","article-title":"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes","volume":"172","author":"Idris","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.10.003_bb0105","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/heartjnl-2015-309164","article-title":"Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes","volume":"102","author":"Anyanwagu","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2017.10.003_bb0110","series-title":"Stata statistical software: release 13","author":"StataCorp","year":"2013"},{"issue":"19","key":"10.1016\/j.ahj.2017.10.003_bb0115","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2017.10.003_bb0120","doi-asserted-by":"crossref","first-page":"h5364","DOI":"10.1136\/bmj.h5364","article-title":"Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)","volume":"351","author":"Lind","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2017.10.003_bb0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4239\/wjd.v5.i1.40","article-title":"Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes","volume":"5","author":"Ahr\u00e9n","year":"2014","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ahj.2017.10.003_bb0130","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/dom.12262","article-title":"BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)","volume":"16","author":"Mathieu","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2017.10.003_bb0135","first-page":"A15","article-title":"Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs. insulin lispro TID added to titrated insulin glargin QD: the 4B study","volume":"56","author":"Wolffenbuttel","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2017.10.003_bb0140","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00125-014-3222-z","article-title":"Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies","volume":"57","author":"Ahren","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2017.10.003_bb0145","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ahj.2017.10.003_bb0150","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/diacare.25.7.1142","article-title":"A prospective study of obesity and risk of coronary heart disease among diabetic women","volume":"25","author":"Cho","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2017.10.003_bb0155","author":"National Institute for Health and Care Excellence (NICE)"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:59:12Z","timestamp":1757570352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317303150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":31,"alternative-id":["S0002870317303150"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.10.003","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}